Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

73.70 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3
Open 73.70
Bid (Size) 72.00 (1)
Ask (Size) 74.00 (1)
Prev. Close 73.70
Today's Range 73.70 - 73.70
52wk Range 38.87 - 91.29
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies. 
Via The Motley Fool

Performance

YTD
+0.52%
+0.52%
1 Month
+3.55%
+3.55%
3 Month
-16.78%
-16.78%
6 Month
+17.06%
+17.06%
1 Year
+26.78%
+26.78%

More News

Read More
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Axsome Therapeutics
Via Benzinga
Expert Ratings for Axsome Therapeutics
Via Benzinga
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
3 Explosive Stocks to Buy Right Now
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Fantastic Growth Stocks to Buy in August
Via The Motley Fool
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
Via InvestorPlace
Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
5 Top Stocks for July
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.